Schizophrenia Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

Schizophrenia Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

DelveInsight has launched a new report on Schizophrenia Market Insights, Epidemiology and Market Forecast-2030

DelveInsight’s “Schizophrenia – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Schizophrenia, historical and forecasted epidemiology as well as the Schizophrenia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Schizophrenia market report provides current treatment practices, emerging drugs, Schizophrenia market share of the individual therapies, current and forecasted Schizophrenia market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Schizophrenia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Schizophrenia is a chronic and severe mental disorder characterized by profound interruptions in thought processes, perceptions, emotional responsiveness and social interactions. Additionally, it can also impair functioning through the loss of an acquired capability to earn a livelihood, or the disruption of studies. The symptoms of schizophrenia fall into three categories: positive, negative, and cognitive. “Positive symptoms” are psychotic behaviors not generally seen in healthy people. Positive symptoms includes hallucinations, delusions and movement disorder and others. “Negative symptoms” are associated with troubles in normal emotions and behaviors. This involves reduced expression and feelings. However, on the other hand, the cognitive symptoms of schizophrenia are subtle in some patients, but for others, they are more severe.


Request for :- Schizophrenia free sample page


Schizophrenia Epidemiology  

The Schizophrenia epidemiology division provide insights about historical and current Schizophrenia patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Report key facts :-

1. According to the World Health Organization, Schizophrenia is a chronic and severe mental disorder affecting 20 million people worldwide.

2. According to the World Health Organization, People with Schizophrenia are 2-3 times more likely to die early than the general population. This is often due to preventable physical diseases, such as cardiovascular disease, metabolic disease and infections.

3. According to “Division of Mental Health and Prevention of Substance Abuse, WHO”, the point prevalence on adults ranges between 1 and 17 per 1000 population, one-year prevalence between 1 and 7.5 per 1000, and lifetime prevalence between 1 and 18 per 1000. Schizophrenia also commonly starts earlier among men.

Schizophrenia Drug Chapters

Drug chapter segment of the Schizophrenia report encloses the detailed analysis of Schizophrenia marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Schizophrenia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases

Schizophrenia Market Outlook

The Schizophrenia market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Schizophrenia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 

This segment gives a thorough detail of Schizophrenia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 

According to DelveInsight, Schizophrenia market in 7MM is expected to change in the study period 2017-2030.

 Key companies working on schizophrenia are given below:- 

1. Minerva Neurosciences Pharma Co. 

2. GW Pharmaceuticals Pharma Co. 

Name of drugs covered are given below:- 

1. Roluperidone

2. GWP42002/GWP4200

Table of Contents

1. Key Insights

2. Executive Summary of Schizophrenia

3. Competitive Intelligence Analysis for Schizophrenia

4. Schizophrenia: Market Overview at a Glance

4.1. Schizophrenia Total Market Share (%) Distribution in 2017

4.2. Schizophrenia Total Market Share (%) Distribution in 2030

5. Schizophrenia: Disease Background and Overview

6. Patient Journey

7. Schizophrenia Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Schizophrenia Treatment and Management

8.2. Schizophrenia Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Schizophrenia Treatment

11. Marketed Products

12. Emerging Therapies

13. Schizophrenia: Seven Major Market Analysis

13.1. Key Findings

13.2. Schizophrenia Market Size in 7MM

13.3. Schizophrenia Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Schizophrenia

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Why should you buy this report?

  • The report will help in developing business strategies by understanding trends shaping and driving the Schizophrenia market
  • To understand the future market competition in the Schizophrenia market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Schizophrenia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Schizophrenia market
  • To understand the future market competition in the Schizophrenia market

Related Reports:- 

1. Schizophrenia – Epidemiology Forecast to 2030

2. Schizophrenia – Pipeline Insights, 2020

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States